Last reviewed · How we verify
PA5108
At a glance
| Generic name | PA5108 |
|---|---|
| Sponsor | PolyActiva Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma (PHASE1)
- Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension (PHASE2)
- Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PA5108 CI brief — competitive landscape report
- PA5108 updates RSS · CI watch RSS
- PolyActiva Pty Ltd portfolio CI